즉시 의료기관(의사)의 진찰을 받으시오.
삼켰다면 즉시 의료기관(의사)의 도움을 받으시오.
P330
입을 씻어내시오.
P361
즉시 오염된 의복을 모두 벗을 것
P403+P233
용기는 환기가 잘 되는 곳에 단단히 밀폐하여 저장하시오.
P405
밀봉하여 저장하시오.
P501
...에 내용물 / 용기를 폐기 하시오.
NFPA 704
0
3
0
Argatroban C화학적 특성, 용도, 생산
개요
Argatroban is a new synthetic antithrombotic agent useful in maintenance
anticoagulation them
ischemic stroke and disseminated intravascular coagulation. In patients on hemodialysis, argatroban is su enor to heparin,
generating a more stable antithrombin effect. Other potential uses include progressing ischemic stroke and disseminated intravascular coagulation.
화학적 성질
White to Off-White Crystalline Solid
Pharmacokinetics
Argatroban is administered subcutaneously because of the low lipophilicity of the drug. The drug is
bound to plasma protein and is metabolized via CYP3A4/5 to the aromatized metabolite and the two
hydroxylated metabolites. The M-1 metabolite retains 20 to 30% of the antithrombotic
activity. Coadministration of argatroban with inhibitors of CYP3A4 does not appear to produce
clinically significant effects. Argatroban is eliminated via biliary secretion into the feces.
Clinical Use
Argatroban has been approved for the prophylaxis and treatment of thrombosis in patients with HIT
(79). Argatroban is a peptidomimetic that binds selectively to the catalytic site of thrombin as a
univalent competitive DTI. Argatroban is available as a mixture of 21-R and 21-S
diastereomers (64:36), with the S-isomer approximately twice as potent as the R-isomer. The
drug is a reversible inhibitor of both free thrombin as well as clot-bound thrombin.